We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cytovance Biologics and Pamlico Biopharma Announce Agreement
News

Cytovance Biologics and Pamlico Biopharma Announce Agreement

Cytovance Biologics and Pamlico Biopharma Announce Agreement
News

Cytovance Biologics and Pamlico Biopharma Announce Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cytovance Biologics and Pamlico Biopharma Announce Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cytovance Biologics, Inc. has announced that they have entered into a development and manufacturing agreement with Pamlico Biopharma, Inc., an Oklahoma City-based clinical stage bio-pharmaceutical company.

Pamlico Biopharma has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.

Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein’s amino acid sequence for GMP manufacture of phase I clinical material.

“With this agreement, Pamlico Biopharma has reached a milestone in the development of a therapeutic antibody product for the treatment of Streptococcus pneumoniae, a leading cause of Severe Community Acquired Pneumonia (SCAP) which can lead to hospitalization and death,” said Clayton Duncan, CEO of Pamlico Biopharma, Inc.

“Cytovance’s state-of-the-art facilities and experienced staff are prepared to deliver the highest quality of development and manufacturing services for Pamlico Bioparma,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics.

Head continued, “We are delighted to be working with such an innovative company that uses technologies from the Oklahoma Medical Research Foundation and advance the treatment of Streptococcus pneumoniae infections that are associated with over 50,000 deaths annually.”

Advertisement